Lexaria Bioscience (LEXX) Total Non-Current Liabilities (2011 - 2023)
Lexaria Bioscience's (LEXX) quarterly Total Non-Current Liabilities came in at $142587.0 in Q2 2023, up 677.51% year-on-year from $18339.0 in Q2 2022, and up 1826.59% quarter-over-quarter from $7401.0 in Q3 2022.
Lexaria Bioscience (LEXX) Total Non-Current Liabilities (2011 - 2023) Analysis & Trends
Lexaria Bioscience has disclosed Total Non-Current Liabilities across 8 years of filings, most recently posting $142587.0 for Q2 2023.
- Total Non-Current Liabilities for Q2 2023 came in at $142587.0, up 677.51% year-over-year; the trailing twelve-month figure through May 2023 was $142587.0 (up 677.51% YoY), and the FY2022 annual result was $7401.0, down 85.19% from the prior year.
- Total Non-Current Liabilities came in at $142587.0 for Q2 2023 at Lexaria Bioscience, up from $7401.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $142587.0 in Q2 2023 to a low of $7401.0 in Q3 2022.
- The 4-year median for Total Non-Current Liabilities is $49989.0 (2021), against an average of $61544.1.
- Across the five-year window, Total Non-Current Liabilities slumped 85.19% in 2022 and surged 677.51% in 2023, its largest moves.
- Lexaria Bioscience's Total Non-Current Liabilities stood at $110821.0 in 2020, then sank by 64.24% to $39629.0 in 2021, then sank by 81.32% to $7401.0 in 2022, then surged by 1826.59% to $142587.0 in 2023.
- The last three Total Non-Current Liabilities figures came in at $142587.0 (Q2 2023), $7401.0 (Q3 2022), and $18339.0 (Q2 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 64.76 Mn |
| 10 | Lexaria Bioscience | 7.17 Mn | 1.65 Mn | 20,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2023 | 142,587.00 |
| Aug 31, 2022 | 7,401.00 |
| May 31, 2022 | 18,339.00 |
| Feb 28, 2022 | 29,080.00 |
| Nov 30, 2021 | 39,629.00 |
| Aug 31, 2021 | 49,989.00 |
| May 31, 2021 | 60,164.00 |
| Feb 28, 2021 | 70,156.00 |
| Nov 30, 2020 | 110,821.00 |
| Aug 31, 2020 | 120,063.00 |
| May 31, 2020 | 28,756.00 |
| Jul 31, 2014 | 957,418.00 |
| Apr 30, 2014 | 1.05 Mn |
| Jan 31, 2014 | 1.47 Mn |
| Oct 31, 2013 | 1.42 Mn |
| Jul 31, 2013 | 1.40 Mn |
| Apr 30, 2013 | 1.48 Mn |
| Jan 31, 2013 | 1.55 Mn |
| Oct 31, 2012 | 1.71 Mn |
| Oct 31, 2011 | 1.68 Mn |